The Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults >= 55 Years Old. A Randomized Triple-Masked Controlled Clinical Trial

Background:
As people age, the cells in the pancreas that produce insulin begin to release less of this hormone, and levels of blood glucose (sugar) rise. This can lead to illnesses such as diabetes. Urolithin A (UA) is a natural nutritional supplement that may improve how the body controls blood glucose.
Objective:
To learn if UA improves levels of insulin and other hormones that help control blood glucose.
Eligibility:
People aged 55 years and older with a body mass index of 27 or higher.
Design:
Participants will have 6 clinic visits over 8 weeks.
Participants will be screened. They will have a physical exam with blood and urine tests and a test of their heart function.
UA gelcaps are taken by mouth every morning at home. Half of participants will take UA. The other half will take a placebo. The placebo looks like the study drug but does not contain any medicine. Participants will not know which they are taking.
Participants will have tests during the study including:
Oral glucose tolerance: Participants will drink a sweet liquid. Blood will be drawn at intervals over the next 3 hours.
Continuous glucose monitor: A sensor with a needle that goes just under the skin will be placed on the upper arm. Participants will wear this sensor throughout the study.
Exercise. Participants will walk on a treadmill while their heart rate, hearth rhythm, and blood pressure are monitored. They will walk in a hallway at normal and fast paces.
Imaging scans of the thigh; scans of the brain are optional....

Start Date02 Sep 2026

Sponsor / Collaborator

National Institute on Aging

NCT07517900

/ CompletedNot Applicable

A Clinical Safety in Use Study of 30 Healthy Volunteers to Investigate the Safety of 1 Test Article Following Repeated Applications

The objective of this study is to investigate the safety of 1 topically applied test article containing Mitopure in a panel of healthy volunteers.

Start Date20 Apr 2026

Sponsor / Collaborator

Amazentis SA

[+1]

NCT07517874

/ CompletedNot Applicable

A Modified Draize Repeat Insult Patch Test in a Shared Panel of 100 Healthy Volunteers to Investigate the Irritation and Sensitization Potential of 1 Test Article Following Repeated Cutaneous Patch Applications

The objective of this study is to investigate the irritation and sensitization potential of 1 topically applied test article containing Mitopure in a shared panel of healthy volunteers by means of repeated cutaneous patch applications under occlusion based on the modified Draize method

Start Date20 Apr 2026

Sponsor / Collaborator

Amazentis SA

[+1]

100 Clinical Results associated with Urolithin A

100 Translational Medicine associated with Urolithin A

100 Patents (Medical) associated with Urolithin A

655

Literatures (Medical) associated with Urolithin A

31 Dec 2026·REDOX REPORT

Urolithin A alleviates vascular remodeling through mitochondrial SIRT3-mediated SOD2 deacetylation and antioxidation in hypertensive rats

Article

Author: Wang, Jing-Xiao ; Zheng, Fen ; Dai, Min ; Zhu, Guo-Qing ; Dong, Hong-Ke ; Xu, Xiao-Yu ; Wang, Yi-Ming

OBJECTIVES:

Urolithin A (UA) is a natural polyphenolic compound produced by gut bacteria. Vascular remodeling contributes to hypertension, and vascular smooth muscle cells (VSMCs) proliferation and migration are important processes in vascular remodeling.

METHODS:

VSMCs were obtained from the thoracic aorta of Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats (SHR). Intraperitoneal injections of UA (50 mg/kg, every 2 days for 4 weeks) were performed in SHR.

RESULTS:

UA attenuated proliferation and migration, reduced mitochondrial reactive oxygen species (mitoROS) levels, and increased SOD2 activity in VSMCs of SHR, which were prevented by SOD2 knockdown. UA promoted mitochondrial short-length SIRT3 (SL-SIRT3) production and SOD2 deacetylation. SIRT3 inhibitor 3-TYP abolished the effects of UA on SOD2 deacetylation, mitoROS levels and VSMCs proliferation and migration. Repeated intraperitoneal injection of UA every 2 days for 4 weeks attenuated vascular remodeling and hypertension, increased SL-SIRT3 levels and SOD2 activity, and reduced SOD2 acetylation and mitoROS levels in aorta and mesenteric arteries of SHR.

CONCLUSION:

UA attenuates VSMCs proliferation and migration in SHR by increasing mitochondrial SL-SIRT3 level, and subsequent SOD2 deacetylation and mitoROS reduction in SHR. Long-term administration of UA attenuates vascular remodeling, hypertension and oxidative stress in SHR.

31 Dec 2026·Gut Microbes

Microbial metabolite Urolithin A protects against inorganic arsenic-induced gut barrier dysfunction in humanized AS3MT mice

Article

Author: Jala, Venkatakrishna Rao ; Banerjee, Mayukh ; Vanwinkle, Zachary Matthew ; Ghosh, Sweta ; Sinha Roy, Kanchan ; Collins, James ; Stýblo, Miroslav

Chronic exposure to inorganic arsenic (iAs) remains a major environmental health concern and is associated with significant gastrointestinal (GI) disorders, including gastroenteritis, diarrhea, and inflammatory bowel disease-like symptoms. Gut microbiota plays a critical role in mitigating arsenic toxicity, as germ-free or antibiotic-treated mice exhibit reduced fecal arsenic excretion and greater tissue accumulation. We previously showed that the microbial metabolite Urolithin A (UroA) protects against iAs-induced cytotoxicity, apoptosis, oxidative stress, and ROS production in vitro. In this study, using humanized AS3MT mice (mouse arsenic methyltransferase gene (As3mt)replaced with human AS3MT, hAS3MT), we evaluated the in vivo effects of iAs and UroA on gut barrier function. Long-term iAs exposure (100 ppb for 28 weeks) significantly reduced expression of tight junction proteins, indicating compromised intestinal barrier integrity. UroA treatment protected hAS3MT mice from iAs-induced gut permeability, inflammation, colon shortening, and elevated colon weight/length ratio. UroA also reduced iAs-induced inflammatory cytokines, myeloperoxidase (MPO) activity and preserved intestinal epithelial cell tight junction protein expression. Further, microbiome and metabolomic analysis suggested that UroA treatment protected from iAs-induced gut microbial dysbiosis, especially restored several beneficial bacterial strains and short chain fatty acids (e.g., acetate and butyrate) and led to gut homeostasis. Together, these findings demonstrate that UroA mitigates iAs-induced gut toxicity and restores microbiota homeostasis.

01 Nov 2026·MITOCHONDRION

Restoration of mitochondrial dynamics and synaptic function by mitophagy enhancers in a tauopathy cell model

Article

Author: Reddy, P Hemachandra ; Reddy, Arubala P ; Kshirsagar, Sudhir

OBJECTIVES:

To evaluate whether mitophagy enhancers-including urolithin A, actinonin, tomatidine, and nicotinamide riboside-can counteract mitochondrial dysfunction and synaptic damage induced by phosphorylated Tau in Alzheimer's disease.

METHODS:

We Used immortalized mouse hippocampal primary HT22 neurons expressing mutant Tau (mTau-HT22). We treated cells with mitophagy enhancers and measured gene and protein levels of mitochondrial dynamics, biogenesis, mitophagy, synaptic markers, assessed cell viability, mitochondrial respiration, and examined mitochondrial morphology via transmission electron microscopy.

RESULTS:

Compared to controls, mTau-HT22 cells exhibited increased mitochondrial fission and reduced fusion, diminished mitochondrial biogenesis, impaired mitophagy and synaptic gene expression, reduced cell survival, lower respiration, and fragmented mitochondria. Treatment with all mitophagy-enhancing compounds improved mitochondrial dynamics-, biogenesis-, and mitophagy-related marker expression together with mitochondrial functional outcomes, with urolithin A showing the strongest effects. Notably, a combined treatment of urolithin A with EGCG further enhanced respiratory function beyond single-agent treatments.

CONCLUSIONS:

Mitophagy enhancers, particularly urolithin A alone or in combination with EGCG, restore mitochondrial and synaptic health in Tau-induced toxicity models. These findings position mitophagy enhancement as a potential therapeutic approach requiring further validation in Alzheimer's disease.

News (Medical) associated with Urolithin A

20 Aug 2026

·www.kcl.ac.uk

Pomegranates could unlock heart failure treatment

Scientists at King’s College London have discovered that urolithin A – a natural compound produced in the body after consuming foods such as pomegranates, walnuts and some berries – improves the heart’s ability to relax, reduces scarring and prevents harmful enlargement of the heart. The finding could give hope to nearly half a million people in the UK who have a type of heart failure where the heart retains its ability to pump blood but becomes stiff and less able to relax between beats, making it harder to fill with blood. This is known as heart failure with preserved ejection fraction and accounts for around half of all heart failure cases. The condition can lead to breathlessness, fatigue, reduced ability to exercise and an overall poor quality of life. Despite its growing prevalence, effective treatments remain relatively limited. The condition is hard to treat because it is driven by many different factors – including ageing, high blood pressure, and diabetes. As the heart can still pump normally, but becomes stiff and does not fill properly, heart failure treatments are less effective. Instead, clinicians focus on managing the underlying conditions and advise lifestyle modifications, such as weight loss and controlling blood sugar. Urolithin A has attracted growing interest in recent years because of its links to healthy ageing and mitochondrial function, a process in the body which generates energy. In a research first, the scientists discovered that urolithin A activates a protein called PKGlα, which plays an important role in both blood vessel function and heart muscle relaxation. Urolithin A targets a specific amino acid on the protein, activating a pathway resulting in cardiovascular benefits. Animal models treated with urolithin A had improved measures of heart function by up to 80% compared to models which were not treated with urolithin A. The laboratory experiment revealed that urolithin A increased the heart tissue’s ability to relax and reduced harmful scarring, also known as fibrosis, compared to controls. The compound also reduced enlargement of heart muscle cells compared to controls, helping to preserve normal cell function. The researchers also tested urolithin A in engineered human heart tissue created from human stem cells. This is a cutting-edge laboratory model that closely mimics the structure and function of human heart muscle. Urolithin A significantly improved tissue relaxation in these cells, suggesting the findings could translate to human cardiac function. Unlike many experimental compounds, urolithin A has already been evaluated in human studies and shows to have a favourable safety profile. While more research is needed before the findings can be translated into treatments for patients, the study identifies both a promising new drug target and a naturally derived compound that could help address a significant challenge in cardiovascular medicine. Dr Joseph Burgoyne, senior author of the study, said: "This type of heart failure remains one of the most challenging forms of heart disease to treat. Our findings identify a completely new therapeutic target and show that urolithin A can activate this pathway to improve heart relaxation and reduce disease severity. This raises the exciting possibility of developing new treatments that improve clinical outcomes and quality of life for people living with the condition. “While there isn’t enough evidence to suggest that people should eat pomegranates to treat heart failure, these findings raise the possibility that dietary approaches that enhance urolithin A production may help alleviate this condition.” Dr Joseph Burgoyne is a cardiovascular scientist at King's College London whose research is uncovering the molecular mechanisms that control the health of the heart and blood vessels. His work focuses on how cells respond to oxidative stress, revealing new ways that blood pressure, heart function and vascular health are regulated. By identifying these fundamental biological processes, his research aims to develop new treatments for cardiovascular diseases such as hypertension and heart failure, with the ultimate aim of improving outcomes for patients. This study was funded by the British Heart Foundation. Professor James Leiper, Director of Research at the British Heart Foundation, said: "Heart failure with preserved ejection fraction (HFpEF) makes up roughly half of all heart failure cases in the UK, and can be debilitating. This early-stage study in experimental models suggests that urolithin A may help to improve the heart tissue’s ability to relax and fill with blood between beats, reducing the harmful changes to the heart muscle seen in HFpEF. "While these findings are promising, the benefits have so far been seen in animals and engineered human tissue, so clinical trials involving people are needed to test if this approach is effective for patients. In the meantime, a healthy, balanced diet remains one of the best ways to look after your heart. Eating plenty of fruit and vegetables is linked to better heart health, but it's important to remember that no single food can prevent or treat heart disease on its own." Health Technology & Science

AHA

29 Jun 2026

·www.einpresswire.com

Nutritional Ingredients Anti-Aging & Longevity Ingredients NAD+ Solution: Medchem Innovation at Vitafoods Europe

CITY OF INDUSTRY, CA, UNITED STATES, June 29, 2026 / EINPresswire.com / -- How can dietary supplement brands effectively translate complex cellular science into stable, market-ready consumer products? At major industry events like Vitafoods Europe, the collective attention of the health and wellness sector has increasingly converged on cellular health, metabolic optimization, and the pathways regulating aging. Among these, nicotinamide adenine dinucleotide (NAD+) enhancement remains a primary focus for product developers seeking validated Nutritional Ingredients Anti-Aging & Longevity Ingredients NAD+ Solution options. For brands navigating this shifting landscape, the challenge is not just identifying high-performing bio-actives, but securing a reliable anti-aging & longevity ingredients supplier capable of delivering batch-to-batch consistency. Essence Medchem Co., Ltd. addresses this precise need by combining twenty years of manufacturing experience with rigorous quality management, transforming emerging longevity concepts into compliant, high-purity raw materials. The commercial interest surrounding longevity science is driven by a practical demand for ingredients that support cellular energy production, DNA repair, and mitochondrial function. At international forums like Vitafoods Europe, industry discussions emphasize that technical execution in manufacturing determines whether a promising molecule succeeds on the retail shelf. Medchem operates at this intersection of science and industrial scaling. Rather than merely supplying standard bulk powders, the manufacturer focuses on the underlying stability and bio-availability of its portfolio. By maintaining strict adherence to ISO 9001, ISO 22000, and FSSC 22000 management systems, Medchem ensures that every batch aligns with international food safety and regulatory expectations, providing a stable foundation for global brand distribution. Technical Optimization in the NAD+ Matrix At the core of modern cellular health formulations are NAD+ precursors, which require exceptional synthetic to maintain biological efficacy over time. Medchem addresses this demand through a specialized portfolio that includes premium β-nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), and NAD+ powder. Each batch is manufactured to achieve a high purity level of 99% or greater via High-Performance Liquid Chromatography (HPLC) verification. This degree of purity prevents the accumulation of unwanted manufacturing degradation products, ensuring that the final dietary supplement remains potent throughout its intended shelf life. Beyond standard material synthesis, material physics plays a critical role in product stability. Standard NMN powder is naturally hygroscopic, making it sensitive to ambient moisture, which can lead to premature degradation during blending and packaging. To resolve this manufacturing vulnerability, Medchem introduces its specialized NMN microcapsule powder. This advanced formulation utilizes a protective coating technology that shields the active ingredient from moisture absorption and masks the inherently sharp taste of the raw material. Furthermore, the microencapsulation process enhances the dissolution profile and bioavailability of the ingredient, allowing brands to develop complex formulations, including multi-ingredient capsules and chewable formats, without compromising the active molecule. Modern formulation strategies are also moving away from single-ingredient applications toward multi-targeted synergetic matrices. Product developers frequently combine NAD+ precursors with other performance bio-actives to address multiple aging mechanisms simultaneously. To support this formulation approach, Medchem supplies premium co-factors such as spermidine trihydrochloride and L-ergothioneine, alongside cellular health components like urolithin A. While NAD+ precursors restore mitochondrial energy pathways, complementary ingredients like urolithin A support mitochondrial renewal by encouraging mitophagial processes. This multi-pathway capability enables brand owners to design comprehensive health products that offer enhanced value to consumers looking for comprehensive wellness support. Supply Chain Reliability and Regulatory Compliance For health brands targeting international markets, navigating regulatory compliance and logistics is often as complex as developing the product itself. The manufacturing facilities of Essence Medchem Co., Ltd. are fully registered with the FDA, and the production lines operate in strict accordance with international standards. The raw materials carry trusted third-party certifications, including Halal and Kosher audits, which are essential for brands intending to enter diverse global regions. This systematic approach to compliance mitigates the regulatory risks associated with cross-border ingredient sourcing. Efficient Distribution Networks Strategic Storage: Medchem maintains dedicated, temperature-controlled warehouse facilities in the City of Industry, California. Substantial Inventory: The facility maintains consistent stock levels, including 1000kg-grade spot reserves of core items like NMN and NR. Rapid Fulfillment: Local warehousing enables fast sample delivery and accelerated commercial shipping, reducing domestic production lead times. This logistical framework is particularly crucial for climate-sensitive longevity molecules. By reducing transit times and ensuring professional climate controls from the factory floor to the regional warehouse, Medchem helps brands maintain an uninterrupted production schedule and minimize inventory holding risks. Comprehensive Solution Integration for Brands The modern functional nutrition market requires a collaborative relationship between ingredient manufacturers and brand owners. Recognizing that different companies possess varying levels of internal development infrastructure, Medchem operates as a comprehensive nad+ solution supplier rather than a simple commodity vendor. The enterprise provides thorough analytical documentation, including detailed Certificates of Analysis (COA), stability data, and safety documentation, giving brand technical teams the necessary data points required for regulatory filings and quality assurance checks. Flexible Manufacturing Capabilities To accommodate diverse business models, the manufacturer offers adaptable service options tailored to specific market entry goals: Custom Formulation: Collaborating with brand development teams to design unique ingredient blends that align with specific marketing claims and nutritional profiles. Private Label Services: Providing pre-formulated, qualified options that allow businesses to launch commercial lines quickly with minimized upfront development costs. OEM Manufacturing: Utilizing advanced industrial infrastructure to manufacture products according to precise client specifications, ensuring exact adherence to proprietary recipes. The diversity of the product portfolio extends to fundamental mineral complexes that support daily metabolic functions. Medchem manufactures a comprehensive suite of highly bioavailable magnesium compounds, including magnesium glycinate, magnesium citrate, magnesium malate, magnesium acetyl taurate, and magnesium L-threonate. These essential minerals are frequently integrated alongside longevity molecules to optimize systemic enzymatic reactions, cellular hydration, and cognitive health formulations. By offering both frontier longevity compounds and foundational nutritional ingredients solution options under a single quality management system, the supplier simplifies purchasing workflows for international procurement teams. As global regulatory landscapes tighten and consumers demand higher transparency, the success of a functional health brand relies heavily on the technical integrity of its supply chain. Through its participation in major industry events like Vitafoods Europe and its ongoing commitment to manufacturing innovation, Essence Medchem Co., Ltd. continues to establish itself as a practical partner for the wellness sector. By resolving the technical challenges of stability, compliance, and delivery, Medchem provides the essential industrial support required to turn advanced longevity science into dependable everyday nutrition. To review detailed technical specifications or explore custom formulation options, visit the official website at https://www.maxmedchem.com/ Essence Medchem Co., Ltd. Essence Medchem Co., Ltd. + +16263716327 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

27 Mar 2026

·www.prnewswire.com

WHAT IF YOU COULD CHOOSE YOUR AGE? LANCÔME LAUNCHES A NEW ERA OF SKIN LONGEVITY WITH THE #1 SELLING UROLITHIN-A SUPPLEMENT¹, NOW IN ADVANCED SKINCARE

INTRODUCING NEW ABSOLUE LONGEVITY MD NEW YORK, March 27, 2026 /PRNewswire/ -- Longevity is no longer just about living longer; it's about maintaining vitality, resilience, and strength as we age. Advances in science and technology now allow us to support not only lifespan, but health span: the years lived in optimal conditions. As life expectancy increases, aging shifts from an inevitable decline to a process that can be supported, optimized, and guided. Continue Reading Absolue Longevity MD Collection Absolue Longevity MD Intercept The Cream Absolue Longevity MD Reset The Serum In beauty, this evolution means changing how we view the role of skincare entirely — expanding our perspective to encompass the visible biological signs of how skin ages, at every stage of life. Skin is not merely aesthetic. As the body's largest organ, it reflects overall health span. While chronological age is fixed, biological age is dynamic, measurable, and influenceable. By targeting visible biological aging signs, skincare can be seen as a powerful pillar of longevity science, offering the opportunity to act on how skin's appearance evolves as we age. LANCÔME AT THE FOREFRONT OF LONGEVITY SCIENCE Lancôme is redefining how beauty approaches aging, shifting from "looking younger" to supporting long-term feelings of vitality and confidence. Drawing on 90 years of scientific heritage and the advanced biological expertise of the L'Oréal Groupe, Lancôme pioneers Longevity Integrative Science™, a proactive approach that targets the visible manifestations of aging mechanisms to support renewal, resilience, and healthy-looking skin over time. Through strategic open-innovation partnerships, including Swiss biotech company Timeline® and Korean beauty tech startup NanoEntek™, Lancôme bridges cutting-edge biotech with high-performance consumer skincare, effectively setting our standard for the beauty industry's future. NEW ABSOLUE LONGEVITY MD Validated by dermatologists* Formulated with Mitopure® by Timeline — the #1 selling longevity Urolithin-A supplement1 — now introduced into advanced skincare. Absolue Longevity MD is Lancôme's first dermatologist-validated skincare range* grounded in Longevity Integrative Science™. Designed to reverse your skin's visible biological age at every life stage, it targets visible aging signs including firmness, suppleness, radiance, fine lines, and smoothness helping to preserve the look of strength, vitality, and radiance over time. *Validated in partnership with Lancôme's advisory board of dermatologists, ensuring thorough review of testing protocols and results; comprehensive ingredient screening for efficacy, safety, and skin compatibility. MITOPURE® BY TIMELINE: FROM BIOTECH TO SKINCARE A central pillar of longevity is mitochondrial health. Mitochondria generate cellular energy, enabling renewal and resilience. As skin ages, mitochondrial efficiency declines, contributing to visible signs of aging. Mitopure® is Timeline's proprietary, highly pure form of Urolithin-A, a postbiotic widely recognized in the longevity field. Backed by more than $50 million in R&D and 15 years of research, Mitopure® powers Timeline's supplement, recommended by a collective of longevity doctors & specialist. It enters skincare on a global scale for the first time through Lancôme. Inspired by biotech innovation, this launch delivers high-performance topical formulas, expanding longevity skincare beyond niche applications. THREE TARGETED INTERVENTION MODELS Integrated across the ANTICIPATE, INTERCEPT, and RESET intervention models, Mitopure® acts as a foundational platform for the whole line. It complements each compound found in the models, helping to support the look of energized, healthy skin throughout its lifespan. Building on this foundation, Lancôme goes beyond a single ingredient, creating proprietary compounds that balance proactive and corrective approaches differently at each stage of the skin's aging trajectory. These compounds are precisely calibrated to respond to the visible biological shifts that occur as skin evolves over time. Each compound is a tailored blend of key ingredients, designed to meet the skin's needs based on its visible biological age—ensuring that every intervention model delivers the right solution, at the right moment.EARLY ONSET ANTICIPATE SKIN'S BIOLOGICAL AGE: UNDER 35Designed to act on visible biological aging signs before they appear. ANTICIPATE CompoundFormulated with Mitopure®, 98.5% pure and micronized form of Urolithin-A, a postbiotic widely recognized in the longevity field1.For a formula with targeted efficacy, Mitopure® is combined with the new proprietary and unique Anticipate compound. This complex fuses Epigenomyl®, Eperuline, Ectoin, and Rose Pro-Xylane with Taurine to anticipate specific visible skin markers according to your visible biological age—the only age you can reverse. Clinically measured visible and invisible resultsVisible aging markers: -16% Incoming fine lines2 invisible aging markers: Up to -50% Skin oxidation31Absolue Longevity MD provides a topical cosmetic way to combat visible signs of aging. Does not function like Mitopure® oral supplement. 2In a Clinical test after 3 months, reduces the look of emerging fine lines. 3With daily use treated vs. untreated skin."Targets aging signs before they appear, fortifying skin's youthful look." – Dr. Annie Black, Lancôme International Scientific DirectorMID-AGE INTERCEPT SKIN'S BIOLOGICAL AGE: 35–55Designed to target visible biological aging signs as they appear. THE INTERCEPT COMPOUND Formulated with Mitopure®, 98.5% pure and micronized form of Urolithin-A, a postbiotic widely recognized in the longevity field1.For a formula with targeted efficacy, Mitopure® is combined with the new proprietary and unique Intercept compound. This complex fuses LHA, Matrixyl™, Niacinamide, and Rose Pro-Xylane with Taurine to intercept specific visible skin markers according to your visible biological age—the only age you can reverse. Clinically measured visible and invisible results Visible aging marker: +76% skin elasticity in just 4 hours2 Invisible aging marker: +4 million new surface cells per day31Absolue Longevity MD provides a topical cosmetic way to combat visible signs of aging. Does not function like Mitopure® oral supplement. 2Instrumental test, 4 hours after application 3Clinical study based on exfoliation over 3 weeks vs. untreated skin"Intercepts visible aging signs as they appear for luminous, youthful looking skin." – Dr. Annie Black, Lancôme International Scientific DirectorMORE MATURE RESET SKIN'S BIOLOGICAL AGE: OVER 55Designed to reset skin's visible biological aging signs after they appear. THE RESET COMPOUNDFormulated with Mitopure®, 98.5% pure and micronized form of Urolithin-A, a postbiotic widely recognized in the longevity field1.For a formula with targeted efficacy, Mitopure® is combined with the new proprietary and unique Reset compound. This complex fuses Senevisium®, Rhamnose, Niacinamide, and Rose Pro-Xylane with Taurine to reset specific visible skin markers according to your visible biological age—the only age you can reverse. Clinically measured visible and invisible results Visible aging marker: +55% skin bounce2 Invisible aging marker: +15% faster surface cell renewal31Absolue Longevity MD provides a topical cosmetic way to combat visible signs of aging. Does not function like Mitopure® oral supplement. 2Instrumental Test, 4 hours after application 3Clinical study based on exfoliation over 3 weeks vs. untreated skin"Reverses visible signs of damage to help restore skin's look of vitality." – Dr. Annie Black, Lancôme International Scientific Director Lancôme's Longevity MD range is available from April 20th, at Lancome-usa.com and select luxury retailers nationwide on May 1st. Anticipate The Cream 1.7 fl. Oz at MSRP $155 Intercept The Serum 1.7 fl. Oz. at MSRP $175 The Cream 1.7 fl. Oz. at MSRP $155 Reset The Serum 1.7 fl. Oz. at MSRP $175 The Cream 1.7 fl. Oz. at MSRP $155 About Lancôme Founded in 1935 by the visionary pioneer Armand Petitjean, with the wish of spreading the spirit and taste of French elegance around the world, Lancôme immediately embodied the essence of beauty. More than ever before, the brand aims to offer every woman the possibility to blossom and embrace her beauty and femininity whatever her age or skin color. Lancôme is present in 135 countries, with about 20,000 beauty advisers in as many points of sale offering sophisticated services and iconic products to an international clientele. Lancôme successfully combines scientific expertise and an intuitive understanding of women's needs to produce major innovations, unique and complementary between skincare, makeup and perfume. Lancôme affirms that happiness is the most attractive beauty. To embody that the brand has chosen charismatic and fully accomplished women such as Julia Roberts, Isabella Rossellini, Olivia Rodrigo, Christy Turlington, and Vanessa Kirby. For more information, please visit or follow us on Instagram: @lancomeofficial, TikTok: @lancome.official, YouTube: @lancomeusa or Facebook: LancomeUS. Leah Pitman, Head of PR & Partnerships – [email protected] Alison Brod Marketing & Communications – [email protected] SOURCE Lancôme 21% more press release views with Request a Demo

100 Deals associated with Urolithin A

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15464

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart failure with normal ejection fraction	Preclinical	United Kingdom	King's College London	20 Aug 2026
Cerebral Hemorrhage	Preclinical	China	Second Affiliated Hospital of Zhengzhou University	01 Nov 2025
Alzheimer Disease	Preclinical	United States	Texas Tech University Health Sciences Center	01 Jul 2025
Rheumatoid Arthritis	Preclinical	China	Zhejiang University	01 May 2025
Skin aging	Preclinical	China	Fudan University	07 Jul 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03283462 (Pubmed \| JAMA Netw Open)	Not Applicable	-	66	Urolithin A	mkobgjbihm(bkfztzgpfq) = xhtfarmqzy bjwdgelhmj (jqlqhoukja )	-	04 Jan 2022
				Placebo	mkobgjbihm(bkfztzgpfq) = iaujnsgjel bjwdgelhmj (jqlqhoukja )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis